RecruitingNot ApplicableNCT04272515

Molecular Characterization for Understanding Biliary Atresia


Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Enrollment

100 participants

Start Date

Feb 7, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.


Eligibility

Inclusion Criteria2

  • confirmed diagnosis of biliary atresia in patients
  • parents of BA patients

Exclusion Criteria1

  • no

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood sampling

collection of blood sample for preparation of DNA

OTHERskin biopsy sampling

preparation of primary cultures of dermal fibroblasts from skin biopsy sample

OTHERexplanted liver of BA patients sampling

cryoconservation of liver tissue for molecular analyses


Locations(2)

Hopital Necker enfants malades

Paris, De, France

PRC Inserm

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04272515


Related Trials